Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cyclerion Therapeutics Inc (CYCN) Com Stk

Sell:$3.44 Buy:$3.46 Change: $0.06 (1.78%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Change: $0.06 (1.78%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Change: $0.06 (1.78%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to develop treatments for serious central nervous system (CNS) diseases through the discovery, development and commercialization of medicines. Its lead product, CY6463 (previously known as IW-6463), is a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator is in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. CY6463 is the core of CNS portfolio with ongoing clinical programs in MELAS and ADv. It is focused on discovering new CNS-penetrant sGC stimulator(s). The Company also has clinical-phase sGC stimulators, praliciguat and olinciguat, and discovery and preclinical-phase compounds.

Contact details

155 Federal Street, Suite 700
United States
+1 (617) 6217722

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$146.28 million
Shares in issue:
43.28 million
United States
US dollar

Key personnel

  • Peter Hecht
    Chief Executive Officer, Director
  • Anjeza Gjino
    Chief Financial Officer, Corporate Secretary
  • Cheryl Gault
    Chief Operating Officer
  • Andreas Busch
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.